Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 4/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | PDE9A | O76083 | 1/20 | 0.38 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077964 | 0.83 | HRH3 (0.54) | PTGS1PTGS2HTR2CHTR2BACACB | |
| SCHEMBL13940565 | 0.81 | GRIN1 (0.46) | GRIN1GRIN2BSLC6A4PTGS1PTGS2 | |
| SCHEMBL20068831 | 0.81 | HRH3 (0.46) | GRIN1GRIN2BSLC6A4PTGS1PTGS2 | |
| SCHEMBL13923530 | 0.81 | GRIN1 (0.41) | GRIN1GRIN2BSLC6A4PTGS1PTGS2 | |
| SCHEMBL10078847 | 0.79 | HTR2C (0.47) | GRIN1GRIN2BSLC6A4HTR2CHTR2B | |
| SCHEMBL16650032 | 0.79 | PLA2G7 (0.38) | GRIN1GRIN2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL24716435 | 0.79 | PTGS1 (0.46) | GRIN1GRIN2BSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL17123796 | 0.77 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL23365192 | 0.77 | GRIN1 (0.48) | GRIN1GRIN2BPTGS1PTGS2ACACB | |
| SCHEMBL24974304 | 0.76 | GRIN1 (0.47) | GRIN1GRIN2BSLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | GRIN1 773/4885GRIN2B 1206/4885SLC6A4 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.